관상동맥 칼슘의 이해와 관리에서 관상동맥 CT 혈관조영술의 가치를 조사하기 위한 전향적, 다기관, 무작위 대조 임상시험 (The Optimal Trial)
관상동맥 칼슘의 이해와 관리에 대한 관상동맥 CT 혈관조영술의 가치를 조사하기 위한 전향적, 다기관, 무작위 대조 시험
The OPTIMAL randomized clinical trial has been designed to compare two imaging strategies and to test the hypothesis that a calcium modification strategy informed by coronary CT angiography (CCTA) will improve procedural efficiency and effectiveness compared with the current standard of care (IVUS-guided PCI) while achieving similar clinical outcomes in patients with hemodynamically significant calcified coronary artery disease.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The OPTIMAL Trial is a prospective, multicenter, randomized controlled study evaluating whether a coronary CT angiography (CCTA)-guided calcium modification strategy can improve the treatment of patients with hemodynamically significant, calcified coronary artery disease undergoing percutaneous coronary intervention (PCI).
Seven hundred patients with flow-limiting stenosis (FFRCT ≤0.80) and moderate-to-severe calcification on CCTA will be randomized 1:1 to either CCTA-guided or intravascular ultrasound (IVUS)-guided calcium modification. The study includes two co-primary endpoints: (1) superiority in final minimal stent area assessed by IVUS, and (2) non-inferiority in 12-month target vessel failure (cardiac death, target-vessel myocardial infarction, or ischemia-driven revascularization).
CCTA-guided strategy uses advanced calcium characterization to inform pre-procedural planning and selection of plaque modification techniques. IVUS-guided strategy follows contemporary intravascular imaging-based criteria for plaque preparation and PCI optimization.
The trial aims to determine whether leveraging non-invasive CT-based calcium assessment can enhance procedural efficiency and stent results while maintaining clinical safety comparable to IVUS-guided PCI.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: CAROLINA FOCELLA
- 전화번호: 001 917 753 6695
- 이메일: cfocella@crf.org
연구 연락처 백업
- 이름: CARLOS COLLET, MD,PhD
- 전화번호: 001 917 753 6695
- 이메일: carloscollet@gmail.com
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- 아직 모집하지 않음
- Bringham and Women's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55407
- 모병
- Minneapolis Heart Institute
-
-
New Jersey
-
Jersey City, New Jersey, 미국, 08837
- 아직 모집하지 않음
- HACKENSACK MERIDIAN HEALTH, Inc
-
-
New York
-
New York, New York, 미국, 14853
- 아직 모집하지 않음
- Weill Medical College of Cornell University
-
New York, New York, 미국, 10032
- 모병
- NewYork-Presbyterian/Weill Cornell Medical Center
-
-
-
-
-
Aalst, 벨기에, 9300
- 모병
- Azorg Hospital, Aalst
-
-
-
-
-
Barcelona, 스페인, 08035
- 모병
- Hospital Universitari Vall Hebron
-
León, 스페인
- 모병
- Hospital Universitario de Leon
-
Madrid, 스페인, 28046
- 모병
- Hospital Universitario La Paz
-
-
-
-
-
Leicester, 영국
- 모병
- University Hospitals of Leicester NHS Trust
-
London, 영국
- 모병
- St Bartholomew's Hospital (Barts Health NHS Trust)
-
London, 영국
- 모병
- St George's University Hospitals NHS Foundations Trust
-
연락하다:
- James Spratt, MD, PhD
-
London, 영국
- 모병
- Guys & St Thomas Nhs Foundation Trust
-
Newcastle, 영국
- 아직 모집하지 않음
- Newcastle Hospitals NHS Foundations Trust
-
Oxford, 영국
- 아직 모집하지 않음
- John Radcliffe Hospital, Oxford
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- The subject must be at least 18 years of age and younger than 85 years old
- Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia (ischemia in the absence of chest pain or other anginal equivalents), unstable angina, or acute myocardial infarction) suitable for PCI. Patients with a clinical indication for revascularization presenting with stable coronary artery disease or stabilized acute coronary syndrome defined as follows unstable angina (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC), patients with NSTEMI without high-risk features such as recurrence of chest pain, ST-segment depression>1mm in ≥6 leads plus STsegment elevation in aVR, life-threatening arrhythmias, mechanical complications of MI, resuscitated cardiac arrest, GRACE risk score>140.
- All target vessels must have reference vessel diameter (visually assessed by CCTA) ≥ 2.5 mm
- Subject must provide written informed consent before any study-related procedure
Exclusion Criteria:
- STEMI as the clinical presentation.
- Uncontrolled or recurrent ventricular tachycardia.
- Hemodynamic instability.
- Hemodialysis or peritoneal dialysis.
- Left main coronary artery stenosis > 50%
- Atrial fibrillation, flutter, or arrhythmias during CT acquisition.
- Previous PCI in the target vessel or CABG.
- BMI ≥ 40 kg/m2
- Insufficient CT quality assessed by the Core lab.
- Comorbidity with life expectancy ≤ 2 years.
- Planned major cardiac or non-cardiac surgery within 24 months after the index procedure Note: Major surgery is any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: Minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.
- The subject has received a solid organ transplant that is functioning or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.
- The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.
- The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest/mediastinum.
- Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3.
- The subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.
- The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, or any prior intracranial bleed, or any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy <2 years for any non-cardiac cause.
- Subject is currently participating in another investigational drug or device clinical study.
- Pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
- Unable to provide written informed consent (IC).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: CT-guide calcium modification strategy
Pre-procedural CT will be used to determine lesion characteristics. |
CT will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent |
|
활성 비교기: IVUS-guide calcium modification strategy
Pre-procedural IVUS will be used to determine lesion characteristics. |
IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Demonstrate that CT-guided calcium modification results in a superior final MSA Minimal Stent Area (MSA) - Imaging Endpoint (Superiority)
기간: Perioperative/Periprocedural
|
Final post-PCI minimal stent area per target lesion, measured by independent core laboratory using intravascular ultrasound (IVUS). Assesses whether CT-guided calcium modification results in superior stent expansion compared with IVUS-guided PCI. |
Perioperative/Periprocedural
|
|
Target Vessel Failure (TVF) - Clinical Endpoint (Non-Inferiority)
기간: 12 months
|
Composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischemia-driven target vessel revascularization (ID-TVR). TV-MI and ID-TVR are defined according to ARC-2 and the Fourth Universal Definition of MI. |
12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Procedural efficiency: Procedure time
기간: During PCI
|
Time from first angiogram to final angiogram |
During PCI
|
|
Procedural efficiency:Radiation dose-area product
기간: During PCI
|
Dose-area product (DAP) recorded during PCI. |
During PCI
|
|
Procedural efficiency: Contrast volume
기간: During PCI
|
Total contrast volume (mL) used during PCI.IVUS-Derived Mechanistic Endpoints (Core Lab) |
During PCI
|
|
Procedural Efficiency: Stent Area on Immediate Post-Stent IVUS
기간: Perioperative/Periprocedural
|
MSA prior to any final IVUS-guided optimization. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Stent Area at Original Minimal Lumen Area (MLA)
기간: Perioperative/Periprocedural
|
Stent area at the co-registered site of the baseline MLA. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Stent Area at Site of Maximum Calcium Arc
기간: Perioperative/Periprocedural
|
Stent area measured at the co-registered IVUS site with maximal calcium arc |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Stent Area at Site of Maximum Calcium Density
기간: Perioperative/Periprocedural
|
Stent area measured at the co-registered CT-identified region of greatest Hounsfield Unit (HU) calcium density. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Relative Stent Expansion
기간: Perioperative/Periprocedural
|
Percentage expansion calculated as: MSA ÷ mean distal reference lumen area × 100. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Number of Calcium Fractures
기간: Post-modification, pre-stent
|
Fractures identified on intermediary IVUS after calcium modification. |
Post-modification, pre-stent
|
|
Procedural Efficiency: Change in Plaque Attenuation
기간: Post-modification, pre-stent
|
Change in IVUS plaque characteristics following calcium modification.Angiographic Endpoints |
Post-modification, pre-stent
|
|
Procedural Efficiency: Final Minimal Lumen Diameter
기간: Perioperative/Periprocedural
|
Minimum lumen diameter by quantitative coronary angiography (QCA) |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Percent Diameter Stenosis
기간: Perioperative/Periprocedural
|
Percent stenosis of treated lesion after PCI, by QCA |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final TIMI Flow Grade
기간: Perioperative/Periprocedural
|
Target vessel flow graded 0-3 based on TIMI criteria. Thrombolysis In Myocardial Infarction (TIMI) Flow Grade is a 0-3 angiographic scale used during coronary angiography to describe how well blood is flowing through a coronary artery.TIMI 0 No perfusion, TIMI 1 Penetration without perfusion, TIMI 2 Partial perfusion TIMI 3 Complete perfusion (normal flow) |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Angiographic Complications
기간: Day of procedure
|
According to Coronary dissection (NHLBI classification) |
Day of procedure
|
|
Procedural Efficiency: Angiographic Complications
기간: Day of procedure
|
According to Coronary perforation (Ellis classification) |
Day of procedure
|
|
Procedural Efficiency: Angiographic Complications
기간: Day of procedure
|
Slow-flow / no-reflow |
Day of procedure
|
|
Procedural Efficiency: Angiographic Complications
기간: Day of procedure
|
Side branch closure (TIMI 0-1) |
Day of procedure
|
|
Clinical & Safety Outcomes: Procedural Success
기간: Perioperative/Periprocedural
|
Final stenosis <30%, TIMI 3 flow, no angiographic complications, and no in-hospital major adverse cardiac events (MACE). |
Perioperative/Periprocedural
|
|
Clinical & Safety Outcomes: Periprocedural Myocardial Infarction (Type 4a MI)
기간: Day 0-1
|
Defined by ARC-2 and 4th Universal Definition of MI (troponin criteria + evidence of ischemia). |
Day 0-1
|
|
Clinical & Safety Outcomes: Stent Thrombosis
기간: Up to 12 months
|
Definite or probable stent thrombosis according to ARC-2 definitions. |
Up to 12 months
|
|
Patient-Reported Outcomes: Residual Angina (SAQ-7 Angina Frequency)
기간: 12 months
|
Residual angina defined as SAQ-7 Angina Frequency score <100. Angina frequency represent how often a patient has had angina (chest pain/discomfort) over a recent recall period. Reported as a 0 to 100 scale: 100 = no angina; 0 = angina occurring very frequently |
12 months
|
|
Patient-Reported Outcomes: Change in Angina (SAQ-7)
기간: Baseline to 12 months
|
Change in angina frequency domain score; positive values indicate improvement. Angina frequency represent how often a patient has had angina (chest pain/discomfort) over a recent recall period. Reported as a 0 to 100 scale: 100 = no angina; 0 = angina occurring very frequently |
Baseline to 12 months
|
공동 작업자 및 조사자
협력자
협력자
간행물 및 유용한 링크
일반 간행물
- Collet C, Sonck J, Vandeloo B, Mizukami T, Roosens B, Lochy S, Argacha JF, Schoors D, Colaiori I, Di Gioia G, Kodeboina M, Suzuki H, Van 't Veer M, Bartunek J, Barbato E, Cosyns B, De Bruyne B. Measurement of Hyperemic Pullback Pressure Gradients to Characterize Patterns of Coronary Atherosclerosis. J Am Coll Cardiol. 2019 Oct 8;74(14):1772-1784. doi: 10.1016/j.jacc.2019.07.072.
- Sonck J, Nagumo S, Norgaard BL, Otake H, Ko B, Zhang J, Mizukami T, Maeng M, Andreini D, Takahashi Y, Jensen JM, Ihdayhid A, Heggermont W, Barbato E, Mileva N, Munhoz D, Bartunek J, Updegrove A, Collinsworth A, Penicka M, Van Hoe L, Leipsic J, Koo BK, De Bruyne B, Collet C. Clinical Validation of a Virtual Planner for Coronary Interventions Based on Coronary CT Angiography. JACC Cardiovasc Imaging. 2022 Jul;15(7):1242-1255. doi: 10.1016/j.jcmg.2022.02.003. Epub 2022 Apr 13.
- Tajima A, Bouisset F, Ohashi H, Sakai K, Mizukami T, Rizzini ML, Gallo D, Chiastra C, Morbiducci U, Ali ZA, Spratt JC, Ando H, Amano T, Kitslaar P, Wilgenhof A, Sonck J, De Bruyne B, Collet C. Advanced CT Imaging for the Assessment of Calcific Coronary Artery Disease and PCI Planning. J Soc Cardiovasc Angiogr Interv. 2024 Mar 26;3(3Part B):101299. doi: 10.1016/j.jscai.2024.101299. eCollection 2024 Mar.
- Monizzi G, Sonck J, Nagumo S, Buytaert D, Van Hoe L, Grancini L, Bartorelli AL, Vanhoenacker P, Simons P, Bladt O, Wyffels E, De Bruyne B, Andreini D, Collet C. Quantification of calcium burden by coronary CT angiography compared to optical coherence tomography. Int J Cardiovasc Imaging. 2020 Dec;36(12):2393-2402. doi: 10.1007/s10554-020-01839-z. Epub 2020 Nov 17.
- Collet C, Collison D, Mizukami T, McCartney P, Sonck J, Ford T, Munhoz D, Berry C, De Bruyne B, Oldroyd K. Differential Improvement in Angina and Health-Related Quality of Life After PCI in Focal and Diffuse Coronary Artery Disease. JACC Cardiovasc Interv. 2022 Dec 26;15(24):2506-2518. doi: 10.1016/j.jcin.2022.09.048. Epub 2022 Nov 30.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- EPIC46-THE OPTIMAL TRIAL
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .